Biopharma Co. Sues Over Cancer Drug Clinical Trial Mix-Up
By Daniel Wilson (September 26, 2012, 2:40 PM EDT) -- Peregrine Pharmaceuticals Inc. on Monday sued a clinical testing company in California federal court, alleging it mixed up the results of a clinical trial for a new cancer treatment, causing Peregrine to have to rescind its promising trial results.
According to the Tustin, Calif.-based biopharmaceutical company's complaint, Fargo, N.D.-based Clinical Supplies Management Inc. ran one of three randomized, double-blind, placebo-controlled Phase II trials for the drug bavituximab as part of a testing services agreement with Peregrine. Bavituximab, a first-of-its-kind monoclonal antibody treatment that prompts the immune system to attack cancer and virus cells, was being tested for treatment of non-small cell lung...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!